CA3221073A1 - Pemafibrate and/or tofogliflozin for use in treating liver disease - Google Patents
Pemafibrate and/or tofogliflozin for use in treating liver disease Download PDFInfo
- Publication number
- CA3221073A1 CA3221073A1 CA3221073A CA3221073A CA3221073A1 CA 3221073 A1 CA3221073 A1 CA 3221073A1 CA 3221073 A CA3221073 A CA 3221073A CA 3221073 A CA3221073 A CA 3221073A CA 3221073 A1 CA3221073 A1 CA 3221073A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- score
- pharmaceutically acceptable
- acceptable salt
- nash
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194088P | 2021-05-27 | 2021-05-27 | |
| US63/194,088 | 2021-05-27 | ||
| PCT/IB2022/054867 WO2022249071A1 (en) | 2021-05-27 | 2022-05-25 | Pemafibrate and/or tofogliflozin for use in treating liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3221073A1 true CA3221073A1 (en) | 2022-12-01 |
Family
ID=82020168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3221073A Pending CA3221073A1 (en) | 2021-05-27 | 2022-05-25 | Pemafibrate and/or tofogliflozin for use in treating liver disease |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2024014524A1 (cg-RX-API-DMAC10.html) * | 2022-07-15 | 2024-01-18 | ||
| CN115991682A (zh) * | 2023-03-21 | 2023-04-21 | 广州佳途科技股份有限公司 | 一种培马贝特-d4的制备方法及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| EP3569250B1 (en) * | 2017-01-11 | 2025-04-30 | Kowa Company, Ltd. | Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease |
-
2022
- 2022-05-25 EP EP22729797.5A patent/EP4346809B1/en active Active
- 2022-05-25 US US18/564,115 patent/US20240277745A1/en active Pending
- 2022-05-25 MX MX2023013886A patent/MX2023013886A/es unknown
- 2022-05-25 BR BR112023024701A patent/BR112023024701A2/pt unknown
- 2022-05-25 CN CN202280050095.0A patent/CN117677385A/zh active Pending
- 2022-05-25 JP JP2023572876A patent/JP2024520020A/ja active Pending
- 2022-05-25 CA CA3221073A patent/CA3221073A1/en active Pending
- 2022-05-25 KR KR1020237044685A patent/KR20240013203A/ko active Pending
- 2022-05-25 AU AU2022282651A patent/AU2022282651A1/en active Pending
- 2022-05-25 WO PCT/IB2022/054867 patent/WO2022249071A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN117677385A (zh) | 2024-03-08 |
| BR112023024701A2 (pt) | 2024-02-15 |
| AU2022282651A1 (en) | 2023-12-07 |
| KR20240013203A (ko) | 2024-01-30 |
| EP4346809A1 (en) | 2024-04-10 |
| MX2023013886A (es) | 2024-04-19 |
| JP2024520020A (ja) | 2024-05-21 |
| WO2022249071A1 (en) | 2022-12-01 |
| EP4346809B1 (en) | 2026-07-15 |
| US20240277745A1 (en) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gawrieh et al. | Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial | |
| US10555929B2 (en) | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy | |
| Bensimon et al. | The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis | |
| EP4706756A2 (en) | Semaglutide for the treatment of non-alcoholic steatohepatitis | |
| BR112020006246A2 (pt) | Método para controle do peso de um sujeito em necessidade | |
| CN114126657A (zh) | 使用fxr激动剂的肝脏疾病的组合治疗 | |
| WO2022249071A1 (en) | Pemafibrate and/or tofogliflozin for use in treating liver disease | |
| US20150139935A1 (en) | Sleep apnea treatment | |
| Ha et al. | Beneficial effects of a curcumin derivative and transforming growth factor-β Receptor I inhibitor combination on nonalcoholic steatohepatitis | |
| TW202114654A (zh) | 包含如sglt 1/2抑制劑的sglt抑制劑之治療 | |
| Zha et al. | Drug interactions between hepatoprotective agents ursodeoxycholic acid or glycyrrhizin and ombitasvir/paritaprevir/ritonavir in healthy Japanese subjects | |
| US20190161483A1 (en) | Methods for using fxr agonists | |
| KR20240146052A (ko) | 체중 감소 및 골격근 질량 보존 방법 | |
| US11179384B2 (en) | Treatment of nonalcoholic fatty liver disease | |
| TW201920269A (zh) | IL-1β 結合抗體之用途 | |
| KR20240146053A (ko) | 상승된 HbA1c를 갖는 대상체에서의 체중 감소 방법 | |
| KR20160014136A (ko) | 패혈증 예방 또는 치료용 약학 조성물 | |
| JP2022523464A (ja) | 脂肪性肝疾患を処置するためのモノアセチルジアシルグリセロール化合物を含む組成物 | |
| HK40012462B (en) | Treatment of nonalcoholic fatty liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250516 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250516 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260330 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260330 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260401 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260410 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260410 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260410 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260413 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260413 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260413 |